Another cost-effectiveness analysis published in JMCP found that tirzepatide 15 mg produced greater quality-adjusted life-years (QALYs) and delayed progression to insulin, with incremental cost-effectiveness ratios (ICERs) of about USD 54,700/QALY (15 mg) and USD 70,100/QALY (10 mg) vs semaglutide 2.0 mg
GHK-Cu, on the other hand, focuses more on repair and support
However, neither ingredient has undergone definitive RCTs with immune function as the primary clinical endpoint in otherwise healthy adults
Tosin laid out the main ones: people hope a lower dose will mean fewer stomach side effects, cost less, still curb appetite without making them feel overly full, and help a limited supply last longer
His ultrasound abdomen did not show any significant abnormalities